Lupin Ltd
₹2328.70
(0.11%)
Thu, 30 Apr 2026, 07:49 am
Health Technology
Pharmaceuticals: Other
24.5KLupin Share Price Live Chart
1 Day
0 (0%)
No Result Found
Summary
Market Cap
105649.52
Net Profit
3306.26
P/B
5.38
Sector P/E
33.29
P/E
28.20
EV/EBITDA
17.31
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
21
ROCE
20.88
Debt/Equity
0.27
EPS (TTM)
108.84
Dividend Yield
0.52
Book Value
429.43
Interest Cover
14.62
Analysis
all
- Dividends per share have increased over the past 10 years.
- Dividends after 3 years are expected to be well covered by earnings (6.1x coverage).
- Lupin's earnings are expected to grow significantly at over 20% yearly.
- Lupin's earnings growth is expected to exceed the India market average.
- Lupin's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- The company is paying a dividend however it is incurring a loss.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Lupin's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Lupin's dividend is below the markets top 25% of dividend payers in India (3.08%).
- Cash flow for Lupin is expected to increase but not above the 50% threshold in 2 years time.
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 46.86 | 46.89 | 46.90 | 46.90 | 46.92 |
| FII | 21.71 | 21.49 | 20.49 | 21.25 | 21.46 |
| DII | 25.32 | 25.58 | 26.55 | 25.56 | 25.41 |
| Public | 6.11 | 6.03 | 6.06 | 6.28 | 6.20 |
| Government | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 2583.03 | 2447.03 | 2380.47 | 2311.03 | 2244.47 | 2175.03 | 2039.03 |
| Fibonacci | 2447.03 | 2395.08 | 2362.99 | 2311.03 | 2259.08 | 2226.99 | 2175.03 |
| Camarilla | 2351.30 | 2338.83 | 2326.37 | 2311.03 | 2301.43 | 2288.97 | 2276.50 |
Pivots Level: Classic
R3
+272
2583.03
R2
+136
2447.03
R1
+69.43
2380.47
S1
-66.57
2244.47
S2
-136
2175.03
S3
-272
2039.03
Moving Average
Period
Value
10-EMA
2310.72
20-EMA
2310.52
30-EMA
2304.86
50-EMA
2284.33
100-EMA
2224.98
200-EMA
2145.65
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 12 Feb 2026 | board-meetings | Quarterly Results | |
| 06 Nov 2025 | board-meetings | Quarterly Results | |
| 14 Jul 2025 | agm | ||
| 25 Jun 2025 | dividend | Final Dividend - Rs. - 12 | 25 Jul 2025 |
| 14 May 2025 | dividend | ₹12.00 Dividend /Share | 25 Jul 2025 |
| 09 Jul 2024 | agm | ||
| 16 Jun 2024 | dividend | Final Dividend - Rs. - 8 | 16 Jul 2024 |
| 06 May 2024 | dividend | ₹8.00 Dividend /Share | 16 Jul 2024 |
| 04 Jul 2023 | agm | ||
| 14 Jun 2023 | dividend | Final Dividend - Rs. - 4 | 14 Jul 2023 |
Peer Comparison
Lupin Ltd
Divis Laboratories Ltd
Cipla Ltd
Dr Reddys Laboratories Ltd
Sun Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Lupin Ltd About
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro- Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, USA, Mexico and Brazil with trading and other incidental and related activities extending to the global markets.
Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln
Founded
1983
Headquarters
CEO
M D Gupta
Employees
Contact
Website
https://www.lupin.com/
investorservices@lupinpharma.com
Phone
91-22-6640 2323
Location
Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055
Lupin Ltd Company History
| Year | History |
|---|---|
| 2020 |
|
| 2021 |
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
Deals
| Client Name | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|
| GENESIS INDIAN INVESTMENT COMPANY LIMITED | Sell | 9423708 | 1816.67 | 08 Mar 2016 |
| GENESIS EMERGING MARKETS L P | Buy | 9423708 | 1816.67 | 08 Mar 2016 |
| INTEGRATED CORE STRATEGIES ASIA PTE LTD | Sell | 3266472 | 1832.77 | 29 May 2015 |
| BLACKROCK INDIA EQUITIES FUND (MAURITIUS) LIMITED | Buy | 8346296 | 1820.43 | 29 May 2015 |
| THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDE | Buy | 2509319 | 509.95 | 30 Nov 2010 |
| GOLDMAN SACHS INVESTMENTS MAURITIUS I LTD | Sell | 874564 | 1217.14 | 29 Oct 2009 |
| CITICORP BANKING CORPORATION FDI | Sell | 933084 | 985 | 11 Aug 2009 |
| CITICORP INTERNATIONAL FINANCE CORPORATION (FDI) | Sell | 1150000 | 835.05 | 20 May 2009 |
| HDFC EQUITY FUND | Buy | 819500 | 835.31 | 20 May 2009 |
| FIDELITY INVESTMENT FUNDS | Buy | 1122388 | 1199.85 | 03 May 2006 |
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800